Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee

A Phase 2a, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of ADL5859 and ADL5747 in Subjects With Moderate to Severe Pain Due to Osteoarthritis of the Knee

The purpose of this study is to determine the efficacy of ADL5859 versus placebo and ADL5747 versus placebo in relieving pain in participants with osteoarthritis of the knee.

Study Overview

• Status: Completed
• Conditions: Osteoarthritis of the Knee
• Intervention / Treatment: Drug: Placebo; Drug: ADL5747; Drug: ADL5859; Drug: Oxycodone CR

• Study Type: Interventional
• Enrollment (Actual): 408
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Florida
    • Daytona Beach, Florida, United States, 32117
      • Covance CRU, Inc
  • Georgia
    • Stockbridge, Georgia, United States, 30281
      • Atlanta Knee and Shoulder Clinic, PC
  • Illinois
    • Chicago, Illinois, United States, 60612
      • University Rheumatoloty Center for Clinical Research
    • Gurnee, Illinois, United States, 60031
      • Clinical Investigation Specialists, Inc
  • North Carolina
    • Salisbury, North Carolina, United States, 28144
      • Cresent Medical Research
    • Wilmington, North Carolina, United States, 28401
      • New Hanover Medical Research
  • Ohio
    • Columbus, Ohio, United States, 43213
      • Columbus Clinical Research
    • Mt Gilead, Ohio, United States, 43338
      • PSB Research
    • Toledo, Ohio, United States, 43623
      • Bone Joint & Spine Surgeons, Inc
  • South Carolina
    • Anderson, South Carolina, United States, 29621
      • Radient Research
  • Texas
    • San Antonio, Texas, United States, 78209
      • Quality Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

• a man or woman between 18 and 75 years of age, inclusive
• for women of childbearing potential, be using an insertable, injectable, transdermal, or combination oral contraceptive deemed highly effective by the United States Food and Drug Administration from the first dose of study medication through the end of the study and have negative findings on pregnancy tests performed at screening and randomization (women who are surgically sterile [for example, hysterectomy, tubal ligation] or postmenopausal [if ≥55 years old, no menses for at least 2 years; if <55 years old, follicle-stimulating hormone concentrations within the postmenopausal range of >40 milli-international units per milliliter (mIU/mL) and 17 β-estradiol levels of <37 picograms per milliliter (pg/mL)] are also eligible to participate)
• for male participants, be surgically sterile or agree to use an appropriate method of contraception (that is, use a barrier method in conjunction with spermicide or have a sexual partner who is surgically sterile, postmenopausal, or using an insertable, injectable, transdermal, or combination oral contraceptive deemed highly effective by the United States Food and Drug Administration) from the first dose of study medication through the end of the study
• have a body weight between 45 and 150 kilograms (kg), inclusive
• have had pain in the index knee for at least the past 6 months
• meet the following criteria for osteoarthritis of the knee established by the American College of Rheumatology (radiographs must have been taken within the last year; if none is available, a radiograph must be taken and the diagnostic criteria must be confirmed before the participant is enrolled in the study): have index knee pain plus at least 1 moderate or definite osteophyte on radiographs. Must also have at least 1 of the following: be more than 50 years old, have morning stiffness for less than 30 minutes, or have crepitus on active motion
• have an average weekly pain score of at least 4.00 on the numeric pain rating scale (NPRS) for the index knee during the baseline week before randomization (to be eligible for randomization, participants must report their NPRS score via the interactive voice-response system (IVRS) for at least 4 of the 7 days immediately before randomization, with the first score being recorded on Day -6)
• if receiving nonselective or selective cyclooxygenase (COX) inhibitors, have a stable daily dose regimen for at least 4 weeks before screening; if receiving nonselective or selective COX inhibitors on an as needed basis, have discontinued use by Day -14; if receiving angiotensin-converting enzyme (ACE) inhibitors, have a stable dose regimen for at least 4 weeks before screening

Key Exclusion Criteria:

• have undergone arthroscopy on the index knee within 6 months before study entry
• have other severe pain that, in the opinion of the investigator, may impair the assessment of the pain due to osteoarthritis
• have a history of hypersensitivity or intolerance to opioids (including tramadol and tapentadol)
• have, as determined by the investigator or the sponsor's medical monitor, a history or clinical manifestations of significant renal, hepatic, hematologic, cardiovascular, metabolic, gastrointestinal, neurologic, psychiatric, or another condition that would preclude participation in the study or affect the outcome of the study
• have taken oral or intramuscular corticosteroids within 30 days before study entry (inhaled or topical corticosteroids are permitted)
• have received intra-articular injections of corticosteroids into the index joint within 12 weeks before screening
• have received intra-articular injections of hyaluronic acid into the index joint within 24 weeks before screening
• currently taking medications other than nonsteroidal anti-inflammatory drugs prescribed for chronic pain (such as duloxetine or pregabalin)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ADL5859; One 50-milligrams (mg) ADL5859 capsule, one 100-mg ADL5859 capsule, and 2 placebo capsules administered orally twice daily (BID) for 14 days	Drug: Placebo; Drug: ADL5859
Experimental: ADL5747; One 150-mg ADL5747 capsule and 3 placebo capsules administered orally BID for 14 days	Drug: Placebo; Drug: ADL5747
Active Comparator: Oxycodone CR; One 10-mg Oxycodone controlled release (CR) capsule and 3 placebo capsules administered orally BID Days 1 through 4 One 20-mg Oxycodone CR capsule and 3 placebo capsules administered orally BID Days 5 through 14	Drug: Placebo; Drug: Oxycodone CR; Other Names: OxyContin
Placebo Comparator: Placebo; Four placebo capsules administered orally BID for 14 days	Drug: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in the Average Pain Score (NPRS) for Week 2	The mean of the daily average scores were calculated from the NPRS pain assessment for the previous 24 hours obtained once a day for at least 4 days from Day -6 through Day 1 (Baseline assessment) and everyday from Day 2 through Day 15 (Treatment Phase assessment). The NPRS is an 11-point scale (0 to 10) with 0 indicating no pain and 10 indicating the worst possible pain.	Baseline, Week 2

Collaborators and Investigators

• Sponsor: Cubist Pharmaceuticals LLC
• Collaborators: Pfizer
• Investigators: Study Director: Bruce Berger, MD, Cubist Pharmaceuticals LLC

Study record dates

Study Major Dates

• Study Start: October 1, 2009
• Primary Completion (Actual): April 1, 2010
• Study Completion (Actual): June 1, 2010

Study Registration Dates

• First Submitted: September 17, 2009
• First Submitted That Met QC Criteria: September 17, 2009
• First Posted (Estimate): September 18, 2009

Study Record Updates

• Last Update Posted (Estimate): August 14, 2015
• Last Update Submitted That Met QC Criteria: July 27, 2015
• Last Verified: April 1, 2015

More Information

Terms related to this study

• Keywords: osteoarthritis; pain; delta opioid receptor agonist
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee; Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Opioid; Narcotics; Oxycodone
• Other Study ID Numbers: 44CL240